Oncotarget

Research Papers:

Long non-coding RNA XIST promotes cell growth and metastasis through regulating miR-139-5p mediated Wnt/β-catenin signaling pathway in bladder cancer

Yangyang Hu, Chao Deng, He Zhang, Jing Zhang, Bo Peng and Chuanyi Hu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:94554-94568. https://doi.org/10.18632/oncotarget.21791

Metrics: PDF 1321 views  |   HTML 1406 views  |   ?  


Abstract

Yangyang Hu1,2, Chao Deng1, He Zhang1, Jing Zhang1, Bo Peng2 and Chuanyi Hu1

1Department of Urology, Gongli Hospital, The Second Military Medical University, Shanghai 200135, China

2Department of First Clinical Medical College, Nanjing Medical University, Nanjing 211166, China

Correspondence to:

Chuanyi Hu, email: chuanyihuglyy@163.com

Bo Peng, email: pengbo6908@163.com

Keywords: lncRNA, XIST, bladder cancer, miR-139-5p, Wnt1

Received: August 24, 2017     Accepted: September 22, 2017    Published: October 10, 2017

ABSTRACT

Bladder cancer is one of the most common urological malignancy all over the world. Recently, long non-coding RNA (lncRNA) XIST has been identified as an oncogenic gene in several type of cancers. However, the expression level and functional role of XIST in bladder cancer remain largely unknown. In the present study, we found that XIST was significantly up-regulated in bladder cancer tissues and cell lines, and was correlated with poor prognosis of bladder cancer patients. Furthermore, XIST knockdown significantly inhibited bladder cancer cell growth and metastasis in vitro and tumor growth in vivo. We also demonstrated that XIST acted as a competing endogenous RNA for miR-139-5p and repression of miR-139-5p could restore the inhibitory effects on bladder cancer cells induced by XIST shRNA. In addition, we identified that Wnt1 was a direct target of miR-139-5p, and XIST played the oncogenic role in bladder cancer by activating the Wnt/β-catenin signaling pathway. Taken together, our study suggested that lncRNA XIST may serve as a prognostic biomarker and a potential therapeutic target for bladder cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21791